---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073304"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:48:11.439139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q4 and FY2025 net loss; zidesamtinib PDUFA set for Sept 18, 2026

## Summary
- Net loss of $118.7M in Q4 2025 and $425.4M for full year 2025.
- Cash, equivalents and marketable securities of $1.4B, runway into 2029.
- FDA accepted zidesamtinib NDA; PDUFA target action date September 18, 2026.
- NDA submission for neladalkib in ALK+ NSCLC planned first half 2026.
- Closed $500M public offering of common stock in November 2025.

## SEC filing metadata
- accession: 0001193125-26-073304
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000119312526073304/0001193125-26-073304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000119312526073304/nuvl-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073304
- JSON: https://secwatch.observer/filing/0001193125-26-073304.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.